Pasithea Therapeutics Retained Earnings vs. Beta

KTTAW Stock  USD 0.02  0.0003  1.50%   
Based on Pasithea Therapeutics' profitability indicators, Pasithea Therapeutics Corp may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Pasithea Therapeutics' ability to earn profits and add value for shareholders.
 
Retained Earnings  
First Reported
2010-12-31
Previous Quarter
-35.3 M
Current Value
-33.6 M
Quarterly Volatility
12.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Price To Sales Ratio is likely to drop to 36.39 in 2024. EV To Sales is likely to drop to -31.1 in 2024. At this time, Pasithea Therapeutics' Total Other Income Expense Net is fairly stable compared to the past year. Income Tax Expense is likely to climb to about 476.6 M in 2024, despite the fact that Operating Income is likely to grow to (15.2 M).
For Pasithea Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pasithea Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pasithea Therapeutics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pasithea Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pasithea Therapeutics Corp over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
0.37
Return On Assets
(0.38)
Return On Equity
(0.63)
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Pasithea Therapeutics Beta vs. Retained Earnings Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Pasithea Therapeutics's current stock value. Our valuation model uses many indicators to compare Pasithea Therapeutics value to that of its competitors to determine the firm's financial worth.
Pasithea Therapeutics Corp is currently regarded as number one stock in retained earnings category among its peers. It is rated fourth overall in beta category among its peers . Pasithea Therapeutics reported Retained Earnings of (35.32 Million) in 2023. Comparative valuation analysis is a catch-all technique that is used if you cannot value Pasithea Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Pasithea Beta vs. Retained Earnings

Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Pasithea Therapeutics

Retained Earnings

 = 

Beginning RE + Income

-

Dividends

 = 
(35.32 M)
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Pasithea Therapeutics

Beta

 = 

Covariance

Variance

 = 
0.82
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Pasithea Beta Comparison

Pasithea Therapeutics is currently under evaluation in beta category among its peers.

Beta Analysis

As returns on the market increase, Pasithea Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Pasithea Therapeutics is expected to be smaller as well.

Pasithea Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Pasithea Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pasithea Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Pasithea Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Pasithea Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-4.7 K-4.9 K
Operating Income-16 M-15.2 M
Income Before Tax-15.5 M-14.7 M
Total Other Income Expense Net471.6 K733.3 K
Net Loss-15.5 M-14.7 M
Income Tax Expense453.9 M476.6 M
Net Interest Income242.4 K254.6 K
Net Loss-16.7 M-17.6 M
Interest Income415.4 K228.5 K
Net Loss(12.65)(13.28)
Net Income Per E B T 1.03  0.79 

Pasithea Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Pasithea Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pasithea Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pasithea Therapeutics' important profitability drivers and their relationship over time.

Use Pasithea Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pasithea Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pasithea Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Pasithea Therapeutics Pair Trading

Pasithea Therapeutics Corp Pair Trading Analysis

The ability to find closely correlated positions to Pasithea Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pasithea Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pasithea Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pasithea Therapeutics Corp to buy it.
The correlation of Pasithea Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pasithea Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pasithea Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pasithea Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Pasithea Therapeutics position

In addition to having Pasithea Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Long Short Funds Thematic Idea Now

Long Short Funds
Long Short Funds Theme
Funds or Etfs that are designed to hedge away market risk by investing in combination of bonds, stocks, derivative instruments as well as short positions to maximize returns irrespective of market conditions. The Long Short Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long Short Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Pasithea Stock Analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.